Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs
摘要:
A novel 2-pyridinone scaffold was rationally designed and synthesized based on the active anti-HIV agent 1 (LAM-trans) via an efficient method. The biological results revealed that some target compounds inhibited HIV-1 reverse transcriptase in the lower micromolar concentration range (IC50 0.089-0.68 mu m). Notably, the most promising compound 25b exhibited extremely potent inhibitory activity against HIV-1 replication with an EC50 value of 0.0563 mu M and the viral selectivity index amounted to 3466.8. Molecular modeling studies were performed, and some SARs were rationalized. (C) 2014 Elsevier Ltd. All rights reserved.
Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs
摘要:
A novel 2-pyridinone scaffold was rationally designed and synthesized based on the active anti-HIV agent 1 (LAM-trans) via an efficient method. The biological results revealed that some target compounds inhibited HIV-1 reverse transcriptase in the lower micromolar concentration range (IC50 0.089-0.68 mu m). Notably, the most promising compound 25b exhibited extremely potent inhibitory activity against HIV-1 replication with an EC50 value of 0.0563 mu M and the viral selectivity index amounted to 3466.8. Molecular modeling studies were performed, and some SARs were rationalized. (C) 2014 Elsevier Ltd. All rights reserved.
A novel 2-pyridinone scaffold was rationally designed and synthesized based on the active anti-HIV agent 1 (LAM-trans) via an efficient method. The biological results revealed that some target compounds inhibited HIV-1 reverse transcriptase in the lower micromolar concentration range (IC50 0.089-0.68 mu m). Notably, the most promising compound 25b exhibited extremely potent inhibitory activity against HIV-1 replication with an EC50 value of 0.0563 mu M and the viral selectivity index amounted to 3466.8. Molecular modeling studies were performed, and some SARs were rationalized. (C) 2014 Elsevier Ltd. All rights reserved.